Algorithms using clinical and genetic data (CYP2C9, VKORC1) are relevant to predict warfarin dose in patients with different INR targets

Thromb Res. 2010 Sep;126(3):e235-7. doi: 10.1016/j.thromres.2010.05.003. Epub 2010 May 31.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Algorithms*
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Blood Coagulation / drug effects*
  • Blood Coagulation / genetics
  • Cytochrome P-450 CYP2C9
  • Drug Dosage Calculations*
  • Drug Monitoring
  • Female
  • Fibrinolytic Agents / administration & dosage*
  • France
  • Genotype
  • Humans
  • International Normalized Ratio
  • Male
  • Middle Aged
  • Mixed Function Oxygenases / genetics*
  • Pharmacogenetics*
  • Phenotype
  • Polymorphism, Genetic
  • Thrombosis / blood
  • Thrombosis / prevention & control*
  • Vitamin K Epoxide Reductases
  • Warfarin / administration & dosage*
  • Young Adult

Substances

  • Fibrinolytic Agents
  • Warfarin
  • Mixed Function Oxygenases
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • VKORC1 protein, human
  • Vitamin K Epoxide Reductases